⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21700252 | 1.00 | — | — | |
| SCHEMBL2547953 | 1.00 | — | — | |
| SCHEMBL7978514 | 1.00 | — | — | |
| SCHEMBL9987305 | 1.00 | — | — | |
| SCHEMBL21620399 | 0.78 | — | — | |
| SCHEMBL8593447 | 0.77 | — | — | |
| SCHEMBL21573898 | 0.74 | — | — | |
| SCHEMBL21395363 | 0.73 | — | — | |
| SCHEMBL14786994 | 0.71 | — | — | |
| SCHEMBL17859638 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441681-B2 | Synthesis of sulfonamide intermediates | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| CN-115515931-B | Synthesis of sulfonamide intermediates | 安进公司 | 2024-10-18 | — | — | CN | disclosed |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230357137-A1 | Synthesis of Sulfonamide Intermediates | AMGEN INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357137-A1 | Synthesis of Sulfonamide Intermediates | AMGEN INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357137-A1 | Synthesis of Sulfonamide Intermediates | AMGEN INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230271981-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-08-31 | — | — | US | disclosed |
| US-20160068545-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068545-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2016-03-10 | — | — | US | disclosed |
| WO-2016033486-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016033486-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| EP-2349997-B1 | ATROPISOMERS OF (HYDROXYALKYL) PYRROLE DERIVATIVES | EXELIXIS INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8487117-B2 | Atropisomers of (hydroxyalkyl) pyrrole derivatives | EXELIXIS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110263673-A1 | Atropisomers of (Hydroxyalkyl) Pyrrole Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2349997-A1 | ATROPISOMERS OF (HYDROXYALKYL) PYRROLE DERIVATIVES | Exelixis, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010042622-A1 | ATROPISOMERS OF (HYDROXYALKYL) PYRROLE DERIVATIVES | EXELIXIS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| US-6277982-B1 | REACTING CARBOHYDRATE, OLIGONUCLEOTIDE, NUCLEOTIDE OR NUCLEOSIDE WITH CYCLIC SULFATE; PRODUCTION OF OLIGONUCLEOTIDES WITH IMPROVED HYBRIDIZATION AFFINITY AND NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2001-08-21 | — | — | US | disclosed |